

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant : Colin Anthony KEMP
Int'l Appln. No. : PCT/GB99/00288
Int'l Filing Date: : 28 January 1999
Serial No. :
Filed : PREPARATION FOR TREATMENT OF ERECTILE
DYSFUNCTION
Art Unit :
Examiner :

CLAIM TO PRIORITY UNDER 35 USC §119

Hon. Commissioner of Patents & Trademarks
Washington, D.C. 20231

Sir:

Under the provisions of 35 USC §119 and 37 CFR §1.55, applicant claims the right of priority based on United Kingdom Patent Application No. 9802078-7 filed 30 January 1998. A certified copy of applicant's priority document will follow in due course.

Respectfully submitted,

MILES & STOCKBRIDGE



Dennis P. Clarke
Registration No. 22,549

DPC/maa

1751 Pinnacle Drive
Suite 500
McLean, VA 22102
Tel: (703) 903-9000
Fax: (703) 610-8686

09/601106



GR 288

The
Patent
Office

INVESTOR IN PEOPLE

5
The Patent Office
Concept House
Cardiff Road
Newport
South Wales

REC'D	31 MAR 1999
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed



Dated

19 MAR 1999



The
Patent
Office

12 FEB 1998 EST 4356-2 201135
201/77100/25.30 1992078.7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P5118/ISH/MDS/42167

2. Patent application number

(The Patent Office will fill in this part)

30 JAN 1998

9802078.7

3. Full name, address and postcode of the or of each applicant (underline all surnames)

FUTURA MEDICAL LIMITED
Antrobus House
18 College Street
Petersfield
Hampshire GU13 4AD
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

England & Wales

07369986001

4. Title of the invention

PREPARATION FOR TREATMENT OF ERECTILE DYSFUNCTION

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

WITHERS & ROGERS
4 Dyer's Building
Holborn
London EC1N 2JT
United Kingdom

Patents ADP number (if you know it)

1776001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 6

Claim(s) 0

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. ☒ We request the grant of a patent on the basis of this application.

Signature *Withers & Rogers*

Date

WITHERS & ROGERS

29 January 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

I S Harrison

0117 925 3030

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

PREPARATION FOR TREATMENT OF ERECTILE DYSFUNCTION

This invention relates to a preparation for topical application to the male sexual organ, especially for the treatment of erectile dysfunction.

Erectile dysfunction is a widespread problem with human males, albeit not commonly discussed in public. It is not regarded as a medical condition susceptible to treatment in the conventional sense being to a large extent caused by a mental condition or at least exacerbated by a loss of confidence following an initial experience caused perhaps by tiredness or an over-indulgence in food or alcohol. Nevertheless, the consequences are serious to the sufferer, resulting in psychological damage and in many cases frustrating the normal fertilisation processes so that artificial insemination procedures must be used if procreation is required. Procedures for overcoming this problem have been proposed which can involve the surgical implantation of stiffening devices as described in GB-A-1476804, US-A-5242391 and other patents. Chemotherapeutical approaches have been proposed which require the injection of vasodilator compositions immediately prior to intercourse. The injection takes place on or near the penile shaft. Neither procedure is attractive and both approaches can result in revulsion or distress on the part of the

partners involved. US-A-5059603 and US-A-4801587 propose topical application of compositions containing vasodilators. US-A-5059603 proposes the use of a composition including a combination of a vasodilator and vasoconstrictor in a carrier intended to assist absorption of the active ingredients through the skin of the penis, the active ingredients being chosen so that the vasodilator acts more quickly than the vasoconstrictor whereby an erection of the penis, having been initiated by the action of the vasodilator, is sustained by the action of the vasoconstrictor. Vasodilators said to be appropriate for use in such compositions include nitroglycerin, papaverine, hydralazine, sodium nitroprusside and phenoxybenzamine, among others. Vasoconstrictors include caffeine, 3-(2-aminoethyl)indole derivatives and adrenaline. US-A-4801587 proposes a composition in the form of an ointment and including a vasodilator selected from papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine and phentolamine mixed in a base with dimethylsulfoxide as a skin-absorption agent. Dimethylsulfonide is also proposed for the same purpose in US-A-5059603.

It has now been found that nitroglycerin (glyceryl trinitrate) can be used as a vasodilator in a composition for topical application to the penis in conjunction with carrier materials without either a vasoconstrictor or

dimethyl sulfoxide, which is known to be a toxic material, and that such compositions are effective for the treatment of erectile dysfunction.

According to one aspect of the present invention, there is provided the use of a combination of compounds in the preparation of a composition for the treatment of erectile dysfunction in human males, the compounds comprising glyceryl trinitrate and lanolin.

According to another aspect of the invention, a method of treatment of erectile dysfunction in males comprises applying to the penis a composition comprising an effective amount of glyceryl trinitrate and lanolin, and causing or permitting the composition to penetrate the skin of the penile shaft.

The carrying out of the method of the invention before sexual intercourse results in an erection of the penis which not only enables subsequent intercourse to take place but also provides for the subject male a mental state of renewed confidence in his ability as a sexual partner and may provide for the other partner a sense of relief from any self-doubt concerning her abilities to stimulate her partner to a state of sexual arousal. The method according to the invention is thus a means of acquisition of a particular state of mental well-being or

a method of enhancing or promoting sexual appeal or sexual confidence, with cosmetic overtones in terms of enhancing the appearance of the male anatomy in the circumstances of intimate sexual activity.

The invention also includes, in a further aspect, the use of glyceryl trinitrate and lanolin in the treatment of erectile dysfunction in human males.

The glyceryl trinitrate acts as a vasodilator according to its established utility for example in the treatment of angina pectoris but it has not hitherto been recognised that in simple combination with lanolin there could be provided an effective treatment of erectile dysfunction in human males.

Glyceryl trinitrate is a material which is per se explosive. For use in the present invention, it is preferably adsorbed on a solid stabilizer in finely-divided particulate form, the particles being in the sub-micron size range to render them capable of passage through the skin. A preferred stabilizer compound is lactose on which the glyceryl trinitrate may be adsorbed at a concentration of from 5 to 20% by weight, for example 10% by weight.

The lanolin acts as a lubricant or moisturiser and

also enhances skin absorption. It is known to be non-toxic and for the purpose of the present invention should be used as a medical grade such as "Medilan" (Trade Mark).

Preferably, compositions according to the invention also include a physical stabilizer such as a paraffin cream; optionally, the compositions contain other ingredients such as fragrances and/or colorants. The paraffin cream, for example provided as White Soft Paraffin B.P., promotes stability of the composition on the skin and also acts as a water-repellant barrier and lubricant.

The composition also includes water to adjust the overall viscosity or consistency and concentration of the active ingredient to the desired levels, bearing in mind that for ease of use the composition should be in the form of a physically-stable suspension of the active ingredient in a creamy emulsion which is sufficiently low in viscosity to be readily applied to and spread over the skin of the penis at ordinary body temperatures.

An example of a composition for use according to the present invention is given below:

<u>Ingredient</u>	<u>Weight %</u>
Glyceryl trinitrate (10% in lactose)	10
Lanolin ("Medilan")	44
White Soft Paraffin B.P.	21
Demineralized Water	25

In use, two grams of the above formulation, which has the form of a white cream, was applied to the glans penis and penile shaft and gently massaged into the skin. The effect was to produce an erection of the penis which was sustained for approximately 45 minutes. The effect in producing an erection may be enhanced by other stimuli of tactile, audio and/or visual nature.